Jared Whitlock

Reporter

Email: jwhitlock@sdbj.com
Phone: 858-634-4636 Extension: 3130

Recent Stories

Following the Local Biotech VC Funding Trail

The San Diego Business Journal frequently chronicles local funding rounds and the big dreams that accompany them. But what about the largest venture capital sources locally?

Tease photo

House Bill Would Further Delay Medical Device Tax

Recently proposed legislation would further push back a 2.3 percent excise tax on medical device makers, San Diego’s ResMed, NuVasive and Ra Medical Systems among them.

Healthcare District Dumps At-Large Elections

HEALTH: Grossmont Makes Move; Palomar Considers Election Change

Under the threat of a lawsuit from a Malibu attorney, one San Diego hospital district is moving to a new type of election system, while another will consider doing so.

Tease photo

Pfizer Move to Transfer 100 Jobs to San Diego

Pharmaceutical behemoth Pfizer is set to close a South San Francisco site and relocate 100 jobs to its research and development campus in La Jolla.

Tease photo

Report: Human Longevity’s Valuation Falls 80%

Human Longevity Inc.’s latest valuation: $310 million, down more than 80 percent from early 2017, according to the Wall Street Journal.

Oxeia Leading the Pack on Potential Concussion Treatments

Oxeia Leading the Pack on Potential Concussion Treatments

Tease photo

Concentration Of Precision Health Companies

Precision health factors in a person’s genes, medical history, environment and more for diagnosis and treatment.

Tease photo

LunaDNA Launches Platform Giving Shares for DNA Data

LunaDNA’s first-of-its-kind platform giving shares for contributing DNA data got approval earlier this week from the U.S. Securities and Exchange Commission.

Ionis’ ALS Drug Candidate Nets $35M Payment from Biogen

Biogen exercised a licensing option and will pay Carlsbad’s Ionis Pharmaceuticals $35 million for a drug candidate aimed at amyotrophic lateral sclerosis, or ALS.

ViaCyte Gets $80M Series D For Pursuit of Diabetes Cure

ViaCyte recently hauled in an $80 million Series D round to advance therapies that the company called a potential “functional cure” for Type 1 diabetes patients.

Tease photo

More stories >>